세계의 재조합 알부민 시장 : 시장 규모, 점유율, 성장 및 산업 분석 - 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of recombinant albumin Market

The global recombinant albumin market continues to expand steadily as advancements in biopharmaceuticals, cell therapy, and drug delivery technologies increase the demand for high-purity serum alternatives. According to the 2024 report, the market was valued at USD 142.8 million in 2024, is expected to reach USD 150.7 million in 2025, and is forecasted to grow to USD 228.5 million by 2032, exhibiting a CAGR of 6.05% during the assessment period. Asia Pacific remained the leading region, accounting for 48.38% of the global market in 2024, supported by expanding therapeutic manufacturing capabilities and strong R&D activity.

Recombinant albumin is rapidly becoming a preferred substitute for human-derived albumin due to its virus-free, scalable, and GMP-compliant production. Its extensive applications in cell culture media, diagnostics, biologics formulation, and drug delivery systems make it a crucial component in modern biomedical manufacturing. As cell and gene therapies expand globally, demand for recombinant albumin continues to increase, driven by its stabilizing, protective, and biocompatible attributes.

Market Dynamics

Market Drivers

A major driver for market growth is the expanding adoption of recombinant albumin in cell and gene therapy. These therapies require highly stable excipients capable of protecting fragile cells and therapeutic molecules during manufacturing and storage. Recombinant albumin enhances viability, reduces aggregation, and supports viral vector manufacturing. This growing integration creates strong long-term demand. In February 2021, for example, Albumedix partnered with the Cell and Gene Therapy Catapult to investigate its albumin solutions for viral vector production, highlighting its increasing strategic importance.

Market Restraints

Despite strong growth potential, the market faces supply limitations due to the complexity of recombinant production. Strict GMP conditions, expensive purification technologies, and lower yields compared to traditional biologics increase production challenges. These constraints can lead to supply shortages and higher costs. In 2022, Mitsubishi Chemical Group Corporation discontinued its recombinant albumin production due to an inability to maintain stable supply, reflecting the difficulties faced by manufacturers.

Market Opportunities

Growing research and development in nanoparticle albumin-bound (nab) drug delivery systems presents significant opportunities. Nab technology enhances solubility and reduces toxicity, making it useful in chemotherapy and biologics formulation. In October 2024, Sandoz launched a generic paclitaxel albumin-bound formulation in the U.S., demonstrating increased adoption of albumin-based delivery systems. Continued advancements in oncology and regenerative medicine are expected to enhance market prospects through 2032.

Market Trends

A key emerging trend is the expansion of manufacturing capacity by leading players. With rising demand from advanced therapy manufacturers, companies are investing in larger bioprocessing facilities and upstream innovation. In March 2025, Yantai Projiji Pharmaceutical Technology announced the expansion of its recombinant albumin production infrastructure, indicating a global shift toward scaling high-purity albumin supply.

Segmentation Overview

By Dosage Form

The solution form dominated the market in 2024 due to reduced contamination risk, high consistency, and ready-to-use formulations. New product launches continue to strengthen this segment, including the February 2025 launch of Optibumin 25 by InVitria, a 25% recombinant albumin solution designed for cell and gene therapy manufacturing.

By Application

The therapeutics segment held the largest share in 2024, driven by recombinant albumin's wide use as an excipient and stabilizer in biologics production. Ongoing collaborations such as Albumedix's partnership with Heartseed in 2023 reinforce the expanding therapeutic applications of recombinant albumin.

By End User

Pharmaceutical and biotechnology companies dominated the end-user segment in 2024, supported by strong R&D investments, manufacturing expansion, and strategic commercialization agreements. In June 2024, Dyadic International partnered with Proliant Health & Biologicals to develop recombinant albumin products, emphasizing the sector's commitment to scaling supply.

Regional Insights

Asia Pacific remained the leading market, valued at USD 69.1 million in 2024, supported by growing biopharmaceutical activity, rising prevalence of chronic diseases, and strong regional collaborations. North America is forecasted to grow steadily, reaching USD 44.5 million by 2025, driven by advanced R&D infrastructure and a strong biologics manufacturing base. Europe is expected to expand to USD 24.0 million in 2025, supported by increasing adoption in therapeutic applications. Latin America and the Middle East & Africa are projected to grow moderately, driven by rising adoption of regenerative medicine and expanding healthcare capabilities.

Conclusion

With the market rising from USD 142.8 million in 2024 to an estimated USD 228.5 million by 2032, recombinant albumin continues to solidify its position as an essential component in biologics, advanced therapies, and drug delivery innovations. Strategic partnerships, increased manufacturing capacity, and expanding therapeutic pipelines will remain key growth drivers over the forecast period.

Segmentation By Dosage Form

• Powder
• Solution

By Application

• Therapeutics
• Diagnostics
• Research

By End User

• Hospital & Clinics
• Pharmaceutical & Biotechnology Industry
• Research Institutes

By Geography

• North America (By Dosage Form, Application, End User, and Country)
  • U.S.
  • Canada
• Europe (By Dosage Form, Application, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Dosage Form, Application, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Dosage Form, Application, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Dosage Form, Application, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in the Market
• 4.2. Regulatory Scenario by Key Countries/ Region, 2024
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.

5. Global Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 5.1.1. Powder
  • 5.1.2. Solutions
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Therapeutics
  • 5.2.2. Diagnostics
  • 5.2.3. Research
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospital & Clinics
  • 5.3.2. Pharmaceutical & Biotechnology Industry
  • 5.3.3. Research Institutes
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 6.1.1. Powder
  • 6.1.2. Solution
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Therapeutics
  • 6.2.2. Diagnostics
  • 6.2.3. Research
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospital & Clinics
  • 6.3.2. Pharmaceutical & Biotechnology Industry
  • 6.3.3. Research Institutes
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 7.1.1. Powder
  • 7.1.2. Solution
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Therapeutics
  • 7.2.2. Diagnostics
  • 7.2.3. Research
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospital & Clinics
  • 7.3.2. Pharmaceutical & Biotechnology Industry
  • 7.3.3. Research Institutes
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 8.1.1. Powder
  • 8.1.2. Solution
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Therapeutics
  • 8.2.2. Diagnostics
  • 8.2.3. Research
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospital & Clinics
  • 8.3.2. Pharmaceutical & Biotechnology Industry
  • 8.3.3. Research Institutes
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 9.1.1. Powder
  • 9.1.2. Solution
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Therapeutics
  • 9.2.2. Diagnostics
  • 9.2.3. Research
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospital & Clinics
  • 9.3.2. Pharmaceutical & Biotechnology Industry
  • 9.3.3. Research Institutes
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 10.1.1. Powder
  • 10.1.2. Solution
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Therapeutics
  • 10.2.2. Diagnostics
  • 10.2.3. Research
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospital & Clinics
  • 10.3.2. Pharmaceutical & Biotechnology Industry
  • 10.3.3. Research Institutes
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles (Overview, Product, SWOT analysis, Recent developments, strategies, financials (based on availability)
  • 11.2.1. InVitria
  • 11.2.2. FUJIFILM Wako Pure Chemical Corporation
  • 11.2.3. Orion Corporation
  • 11.2.4. Sartorius AG
  • 11.2.5. Thermo Fisher Scientific Inc.
  • 11.2.6. Merck KGaA